株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医用画像の世界市場:四半期調査 (2019年第1四半期)

Global Medical Imaging Industry Quarterly Tracker, Q1 2019

発行 Frost & Sullivan 商品コード 913144
出版日 ページ情報 英文 55 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.71円で換算しております。
Back to Top
医用画像の世界市場:四半期調査 (2019年第1四半期) Global Medical Imaging Industry Quarterly Tracker, Q1 2019
出版日: 2019年09月25日 ページ情報: 英文 55 Pages
概要

医用画像・インフォマティクス産業は新しい製品やソリューションが次々と市場投入される中、急速に発展を遂げています。

当レポートでは、世界の医用画像の市場を四半期ベースで調査し、臨床部門における主要動向、新製品・ソリューションの市場展開・導入状況、新製品の機能・能力、FDA・CE承認の動向、FDA・CEリコールの動向、関連法規制・償還政策などの動向、M&A・企業間の提携などの動向、注目のイベントなどをまとめています。

エグゼクティブサマリー

競合環境

  • 長期事業契約
  • 新製品の市場投入
  • 企業ハイライト
  • 事業協力
  • FDA承認
  • CE承認
  • FDAリコール

政策・法規制

臨床動向

イベントハイライト

総論

  • 総論
  • 免責事項

付録

FROST & SULLIVANについて

目次
Product Code: MEDA-50

Quarterly Edition of Trends in Medical Imaging and Informatics Covering Competition, Policy, Regulatory, and Clinical Areas

The medical imaging and informatics industry is evolving rapidly, and new products and solutions are launched every other day. As the reimbursement environment is transitioning from fee-for-service to value-based payment, vendors' business models and value propositions are undergoing drastic changes. New evidence regarding the use of certain techniques in imaging is influencing changes in the standard of care. On a macro level, the government's policies on reimbursement and regulations tend to impact the performance of industry participants, if their internal teams delay the calibration of the strategic actions needed to thrive in this new environment.

To help its clients address challenges in an intensely competitive environment, Frost & Sullivan has introduced the Medical Imaging and Informatics Quarterly Insights tracker that will monitor market factors and significant events and qualitatively assess their impact on the industry; this will cover the diagnostic imaging, image-guided therapies, and imaging informatics segments.

Research Scope:

The scope of this deliverable covers the following segments:

Clinical Trends

  • Disruptive trends that impact the current ‘gold standard'
  • Trends that indicate the clinical adoption of new solutions/products
  • Important announcements from associations such as RSNA, ESR, ACR, and ACC

Competition

  • New product launches and capabilities
  • Mergers and acquisitions
  • FDA and CE approvals
  • Major FDA and CE recalls/warnings

Policies and Regulations

  • Region-specific introduction of new regulatory approvals
  • Reimbursement achievements or setbacks

Event Highlights

  • Major event highlights in the quarter that cover important themes - this is derived by studying the messaging and communications, product launches, and product promotions at the events

Table of Contents

Executive Summary

  • Methodology
  • Scope
  • Key Takeaways

Competition

  • Competition-Long-term Business Contracts
  • Competition-Long-term Business Contracts (continued)
  • Competition-Long-term Business Contracts (continued)
  • Competition-New Launches
  • Competition-New Launches (continued)
  • Competition-New Launches (continued)
  • Competition-Corporate Highlights
  • Competition-Corporate Highlights (continued)
  • Competition-Business Collaboration
  • FDA Approvals from Top-tier Companies (January-March 2019)
  • FDA Approvals from Other Companies (January-March 2019)
  • Notable CE Approvals
  • FDA Recalls
  • FDA Recalls (continued)

Policies and Regulations

  • Policies and Regulations
  • Policies and Regulations (continued)
  • Policies and Regulations (continued)
  • Policies and Regulations (continued)
  • Policies and Regulations (continued)
  • Policies and Regulations (continued)
  • Policies and Regulations (continued)

Clinical Trends

  • Clinical Trends
  • Clinical Trends (continued)
  • Clinical Trends (continued)
  • Clinical Trends (continued)
  • Clinical Trends (continued)
  • Clinical Trends (continued)
  • Clinical Trends (continued)

Event Highlights

  • Event Highlights
  • Event Highlights (continued)
  • Event Highlights (continued)

Conclusion

  • Conclusion
  • Legal Disclaimer

Appendix

  • List of Exhibits

The Frost & Sullivan Story

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360º Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top